Clinical Trial Update: Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL [Phase 1, Phase 2]

View source ↗

Summary

This clinical trials update describes a phase 1/2 study of a CD19 CAR T-cell therapy with CD34 selection for patients with CD19-positive relapsed/refractory B-c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• CD19 CAR T-cell therapy with CD34 selection

Snippet

Sponsor: Medical University of South Carolina | Conditions: B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: RECRUITING